Iovance Biotherapeutics FY 2020: net loss $259.6M; diluted EPS −$1.88

Key figures from this report

These are the numbers Iovance Biotherapeutics reported for the year ended Dec 31, 2020, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

1. Net income−$259.6MNo year-earlier figure tagged10-K income statement, on EDGAR
2. Diluted EPS−$1.88No year-earlier figure tagged10-K income statement, on EDGAR
3. Cash and cash equivalents$67.3MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
4. Cash from operations−$205.1MNo year-earlier figure tagged10-K cash flow statement, on EDGAR

Every year in the financial tables